This work was supported in part by grants from the Boots Company (USA). Shreveport, Louisiana.Address for correspondence: Kanu Chatterjee, MB, FRCP, University of California, Moffitt Hospital, Room 1186, Box 0124, San Francisco, California 94143.
Objectives. The aim of this study was to evaluate the immediate and long-term systemic and coronary hemodynamic, metabolic and neurohormonal effects of flosequinan in patients with congestive heart failure.Background. Preliminary studies have shown that this new long-acting oral systemic vasodilator may have beneficial effects in patients with heart failure.Methods. Thirteen patients with congestive heart failure were studied. Systemic and coronary hemodynamic, metabolic and neurohormonal effects of flosequinan were assessed acutely with repeat systemic hemodynamic studies after 6 weeks of treatment.Results. The administration of flosequinan acutely and after long-term treatment, resulted in a significant increase in cardiac index, stroke work index and stroke volume index with a reduction in systemic and pulmonary vascular resistances. The improvement in ventricular function was associated with an improvement in left ventricular efficiency without a change in myocardial oxygen consumption or coronary sinus blood flow.Myocardial oxygen extraction and net myocardial lactate extraction also did not change significantly with flosequinan therapy. Systemic catecholamine levels and myocardial catecholamine balance did not change. Plasma arterial and coronary sinus atrial natriuretic factor concentrations were elevated at baseline; the latter concentrations at the level of the great cardiac vein were significantly higher than those of arterial concentrations, indicating increased left ventricular release of atrial natriuretic factor in congestive heart failure. Both arterial and coronary sinus atrial natriuretic factor levels were significantly reduced with the administration of flosequinan at peak effect in association with an improvement in systemic hemodynamics.Conclusions. Flosequinan therapy in patients with congestive heart failure results in a sustained beneficial hemodynamic action and improved cardiac performance without an increase in metabolic demand or activation of the sympathetic nervous system.
Continuing Medical Education through JACC is a convenient way to fulfill your CME requirements while learning important information about the latest advances in cardiovascular medicine.
April 2013- JACC CME Activity Repeat Revascularization and Outcome
March 2013- JACC CME Activity Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
Feb 2013- JACC CME Activity Results from the BARI 2D Trial
Jan 2013- JACC CME Activity Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope
Dec 2012- JACC CME Activity Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Nov 2012- JACC CME Activity A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials
Oct 2012- JACC CME Activity Radiofrequency Ablation of Premature Ventricular Ectopy Improves the Efficacy of Cardiac Resynchronization Therapy in Nonresponders
Sept 2012- JACC CME Activity Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease
Aug 2012- JACC CME Activity Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)
July 2012- JACC CME Activity Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction
For previous CME quizzes, please follow this link to CardioSource Lifelong Learning and MOC.
Please read the other comments before posting. Contributors must reveal any conflict of interest. Comments are moderated and will appear on the site at the discretion of The American College of Cardiology editorial staff.
* = Required Field
Disclosure of Any Conflicts of Interest* (applies to the past 5 years and foreseeable future) Indicate any potential conflicts of interest of each author below, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, speakers bureau, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents filed, received, or pending). If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
You don’t need to be a member of the ACC, but you do need to complete a brief registration on CardioSource before you can sign-up for eTOC alerts (weekly email with the JACC table of contents and weekly email with Online Before Print articles.)
Register
Subscribe to the Journal of the American College of Cardiology for full-text access to content
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athensand Shibbolethare access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.